Treatment of Progressive Multifocal Leukoencephalopathy with Nivolumab

N Engl J Med. 2019 Apr 25;380(17):1674-1676. doi: 10.1056/NEJMc1816198. Epub 2019 Apr 10.

Authors

Ondine Walter¹, Emmanuel Treiner², Fabrice Bonneville¹, Catherine Mengelle¹, François Vergez³, Fleur Lerebours¹, Pierre Delobel¹, Roland Liblau², Guillaume Martin-Blondel⁴; Immune Checkpoint Inhibitors in PML Study Group

Affiliations

¹ Toulouse University Hospital, Toulouse, France.
² Centre de Physiopathologie Toulouse-Purpan, Toulouse, France.
³ Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France.
⁴ Toulouse University Hospital, Toulouse, France martin-blondel.g@chu-toulouse.fr.

PMID: 30969500
DOI: 10.1056/NEJMc1816198

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Blood / virology
Brain / diagnostic imaging
CD4-Positive T-Lymphocytes / physiology
CD8-Positive T-Lymphocytes / physiology
Cerebrospinal Fluid / virology
Female
Humans
Immunologic Factors / therapeutic use*
JC Virus / isolation & purification*
Leukoencephalopathy, Progressive Multifocal / diagnostic imaging
Leukoencephalopathy, Progressive Multifocal / drug therapy*
Lymphocyte Count
Magnetic Resonance Imaging
Middle Aged
Nivolumab / therapeutic use*
Programmed Cell Death 1 Receptor / antagonists & inhibitors*
Programmed Cell Death 1 Receptor / metabolism
Viral Load
White Matter / diagnostic imaging
White Matter / pathology

Substances

Immunologic Factors
PDCD1 protein, human
Programmed Cell Death 1 Receptor
Nivolumab